Accuracy of Financial Disclosures in US-Based Rheumatology Journals
Additional supplementary information cited in this article can be found online in the Supporting Information section (https://onlinelibrary.wiley.com/doi/10.1002/acr.25211).
Author disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/acr.25211.
Transparency of disclosure in publication is necessary for readers to be aware of any potential conflicts of interest (PCOIs). Past studies of accuracy of disclosure in rheumatology journals have focused exclusively on clinical practice guidelines and not research works. We assessed discrepancy in reporting PCOIs in clinically oriented manuscripts published in the three top-ranked (by impact factor) US-based general rheumatology journals.
We reviewed disclosures provided by first, second, and last authors of 50 published clinically oriented articles in each of the three top-ranked general US rheumatology journals. For each author, we extracted payment reports from the Open Payments Database (OPD) related to consulting fees, honoraria, and speaker or faculty compensation. We defined a PCOI as a payment received from a company with an ongoing clinical trial or a medication on the market related to the manuscript's subject matter within the 36 months before the online publication date. We additionally analyzed each author individually to determine whether their reported disclosures matched PCOIs from the OPD.
Of 150 articles analyzed, 101 included authors with PCOIs. Ninety-two of these 101 publications (92%) contained inaccurate (non- or under-) disclosures. Among 135 authors with PCOIs, 118 reported inaccurately (87%). All 14 articles that published clinical trial results (and all 23 of their qualifying authors) had disclosure inaccuracies.
Inaccurate financial disclosure by authors remains an issue in clinically oriented research studies reported in top rheumatology journals. Improved community education and firmer expectations would permit readers to better assess any possible impact of PCOIs on publications.
|acr25211-sup-0001-Disclosureform.pdfPDF document, 6.2 MB||
|acr25211-sup-0002-TableS1.docxWord 2007 document , 15.5 KB||
Supplemental Table 1. Instances of non-disclosed and under-disclosed PCOI and mean change in dollar amount per author for two different time frames. The original time frame consisted of a 36 month look back period from online publication date and the shifted time frame consisted of a 36 month look back period from paper submission date. The top 5 unique authors with the highest number of PCOIs were analyzed from each journal.
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
- 1 US Centers for Medicare & Medicaid Services. Open Payments Data. 2022. URL: https://openpaymentsdata.cms.gov/
- 2, , , et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? Ann Intern Med 2021; 174: 353–61.
- 3, , , et al. Association of author's financial conflict of interest with characteristics and outcome of rheumatoid arthritis randomized controlled trials. Rheumatology (Oxford) 2019; 58: 776–85.
- 4, , , et al. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncol 2018; 4: 1426–8.
- 5, , , et al. Evaluation of financial conflicts of interest among physician-authors of American College of Rheumatology clinical practice guidelines. Arthritis Rheumatol 2020; 72: 1427–34.
- 6, , , et al. Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry. Medicine (Baltimore) 2017; 96:e5711.
- 7, , , et al. Discrepancies in self-reported financial conflicts of interest disclosures by physicians: a systematic review. BMJ Open 2021; 11:e045306.
- 8, , , et al. Authors of clinical trials seldom reported details when declaring their individual and institutional financial conflicts of interest: a cross-sectional survey. J Clin Epidemiol 2020; 127: 49–58.
- 9, , , et al. Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. Cancer 2019; 125: 4069–75.
- 10, , , et al. Analysis of American College of Cardiology/American Heart Association guideline author self-disclosure compared with Open Payments Industry Disclosure. Circ Cardiovasc Qual Outcomes 2019; 12:e005613.
- 11 The top 20 drugs by worldwide sales in 2020. Fierce Pharma. 2021. URL: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales/
- 12, , , et al. Industry payments to practicing US rheumatologists, 2014-2019. Arthritis Rheumatol 2021; 73: 2138–44.
- 13, , , et al. Publication bias in clinical research. Lancet 1991; 337: 867–72.
- 14, . Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004; 6: R250–5.
- 15, , , et al. Author self-disclosure compared with pharmaceutical company reporting of physician payments. Am J Med 2016; 129: 59–63.
- 16, , , et al. Accuracy between AJSM author-reported disclosures and the Centers for Medicare and Medicaid Services Open Payments Database. Am J Sports Med 2018; 46: 969–76.